

ENDURING MATERIAL LEARNER NOTIFICATION

THC – Total Health Conferencing
Breast Cancer Social Media Pop-Up CME
Date of CE Release: August 27, 2020
Date of CE Expiration: August, 2023
Location: Online

Acknowledgement of Financial Commercial Support

No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by

by

Amedco LLC and Total Health Conferencing. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

First	Last	Commercial Interest	
Rachael	Kilby	NA	Amedco LLC designates this enduring material for a maximum of
Reshma	Mahtani	Genentech:Research Grant Overall Principal Investigator,Agendia, Amgen, Celgene, Esai, Genentech, Lilly, Novartis, Pfizer, Puma:Consultant	1.00 AMA PRA Category 1 Credits™.

Physicians should

claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

Pharmacists

Amedco LLC designates this activity for a maximum of 1.00 knowledge-based CPE contact hours.

Objectives - After Attending This Program You Should Be Able To

1. Review and discuss the available treatment options for this patient population and discuss how we might individualize therapy in the future to optimize the balance of efficacy and toxicity.
2. Review the addition of pertuzumab to a trastuzumab-based adjuvant regimen and discuss improvement of pathologic complete response rates and invasive disease-free survival.
3. Review the addition of neratinib for patients with high-risk disease and discuss improvement disease-in free survival.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First	Last	Commercial Interest
Lee	Schwartzberg	Amgen:Research Grant Overall Principal Investigator,Pfizer, AstraZeneca, Novartis, Genentech, Helsinn:Consultant,PUMA:Speakers Bureau
Sara	Tolaney	Genentech/Roche:Consultant,Genentech.Roche:Research Grant Site Principal Investigator,Puma:Consultant,Seattle Genetics:Consultant,Seattle Genetics:Research Grant Site Principal Investigator,AstraZeneca:Consultant,AstraZeneca:Research Grant Site Principal Investigator,Daiichi-Sankyo:Consultant

How to Get Your Certificate:

1. CME Link: <https://workshop-evaluator.herokuapp.com/evaluation/7545>
2. Evaluate the meeting.
3. Print all pages of your certificate for your records.

Questions about your credit certificate? Email Certificate@AmedcoEmail.com